Australia markets open in 7 hours 34 minutes
  • ALL ORDS

    7,328.00
    +2.20 (+0.03%)
     
  • AUD/USD

    0.7761
    +0.0021 (+0.27%)
     
  • ASX 200

    7,065.60
    +2.10 (+0.03%)
     
  • OIL

    63.37
    +0.24 (+0.38%)
     
  • GOLD

    1,771.80
    -8.40 (-0.47%)
     
  • BTC-AUD

    71,192.90
    -666.17 (-0.93%)
     
  • CMC Crypto 200

    1,249.70
    -49.25 (-3.79%)
     

C2N Diagnostics, Boosted by Growth from the PrecivityAD™ Blood Test, Named By Fierce Medtech As a ‘Fierce 15’

·3-min read

One of the ‘Most Promising Private Companies’

C2N Diagnostics, which recently became the first to offer a widely accessible blood test to help physicians with Alzheimer’s disease diagnosis, continues to reach important roll-out milestones.

All of these developments have led Fierce Medtech, an international news service for the med tech industry, to name C2N one of its Fierce 15 for 2020. The outlet says it selected the company for this designation because it’s "one of the most promising private companies in the industry."

Dr. Joel Braunstein, CEO of C2N Diagnostics, says, "We’ve exceeded the sector’s expectations with the introduction of the PrecivityAD™ blood test and it’s gratifying for our entire team and our partners to see this kind of recognition. Most importantly, we’re providing patients, doctors and advocates with the kind of diagnosis breakthrough they’ve been wanting."

Braunstein adds that the test’s benefits include the fact that it’s a precise quantitation of certain measurements, easy to administer and a way for clinicians to reliably determine the probability of Alzheimer’s pathology in patients with early cognitive impairment.

"Each member of this year’s class of Fierce 15 stands out in a different way, but they all overcame a year of unforgettable obstacles, making each of their successes that much more significant — and all have the potential to deliver changes in healthcare that promise to outlast this pandemic," says Conor Hale, associate editor of Fierce Medtech.

Rhode Island recently approved C2N’s lab to conduct tests for patients in that state; this development means the company can now offer the PrecivityAD™ blood test in 47 states, the District of Columbia and Puerto Rico.

Since last year, C2N has been analyzing samples in compliance with U.S. CLIA regulations, and the PrecivityAD™ blood test has also met the quality standards needed to receive the CE Mark from the European Union.

The company has received additional recognition for its efforts:

  • Alzheimer’s Drug Discovery Foundation (ADDF) named the PrecivityAD™ blood test one of its top five highlights of 2020. Howard Fillit, MD, the founding executive director and chief science officer of ADDF, says, "the fact that there is now an Alzheimer’s blood test on the market is just amazing."

  • NBC News put the PrecivityAD™ blood test on its list of top 2020 medical accomplishments.

  • MedPage Today named it one of its 2020 big breakthroughs.

  • TheScientist selected it as one of the biggest science news stories of the year.

About C2N Diagnostics, LLC

C2N’s Diagnostics’ vision is to bring Clarity Through Innovation™. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. Its lead commercial product, PrecivityAD™, is a mass spectrometry-based test that measures in blood multiple analytes including Aβ42, Aβ40, and apolipoprotein E isoforms. This test predicts brain amyloid plaques as determined by PET scan results and in early 2019 it received a Breakthrough Device Designation from the U.S. Food and Drug Administration. For more information visit www.C2N.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005491/en/

Contacts

Adam Shapiro
Adam.Shapiro@ASPR.bz
202-427-3603